#Intermapper full
#Intermapper free

We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC Group is a leading market research company that offers management strategy and market research worldwide. Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization. Comprehensive Mapping of the Competitive Landscape.Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other).

Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others).

Europe (Germany, France, United Kingdom, Italy, Spain, Others).

Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. The competitive landscape of the industry has also been examined along with the profiles of the key players beingĪbbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Global Pharmacogenomics Market 2022-2027 Analysis and Segmentation:

#Intermapper full

Moreover, rapid technological advancements have resulted in the introduction of newer and upgradation of existing laboratories, which is attracting numerous investors from across the healthcare industry, thereby creating a positive outlook for the market.Īsk Analyst for Instant Discount and Download Full Report with TOC & List of Figure: Other than this, the increasing prevalence of different types of cancer is also fueling the market growth as targeted therapy has proven to improve the survival rates of patients and decrease redundant costs.

Additionally, there is a rising preference toward precision medicine on account the emerging need for improved drug efficacy and safety, which is further contributing to the growth of the market.

#Intermapper free

Request Free Sample Report (Exclusive Offer on this report): Ī significant rise in the research and development (R&D) expenditure activities and an increase in the instances of adverse reactions of drugs are some of the primary factors that are currently driving the global pharmacogenomics market growth. These observations will be integrated into the report. We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. Pharmacogenomics also helps in designing precise methods of measuring appropriate drug dosages and the development of more efficient vaccines. Overall, it decreases healthcare costs via reduced adverse drug reactions, minimal number of failed clinical trials, and lesser time consumption in the drug approval process. The drug development process through pharmacogenomics consists of various analyses, which include drug receptors, drug uptake, drug breakdown, and targeted drug development. Pharmacogenomics studies variations in certain proteins, such as liver enzymes, that affect the performance of a drug. It helps healthcare providers to select and develop safe, effective medications that can be tailored to the genetic design of a person. Pharmacogenomics is a field of research that studies the relation between the deoxyribonucleic acid (DNA) of an individual and their response to a drug. Looking forward, IMARC Group expects the market to reach US$ 11.3 Billion by 2027, exhibiting a CAGR of 9.3% during 2022-2027. According to the latest report by IMARC Group, titled, “Pharmacogenomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” the global pharmacogenomics market reached a value of US$ 6.6 Billion in 2021.